New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:35 EDTGILD, INFIGilead study 'alarming,' says Stifel
Stifel believes that a study of Gilead's (GILD) GS-9973+idelalisib - which it says terminated early due to the development of severe pneumonitis in nine patients - is "alarming." The firm adds that Gilead's results may prevent Infinity Pharmaceuticals (INFI) - which the firm thinks has plans to combine IPI-145 with a Btk inhibitor - from finding future commercial partners. However, it keeps Buy ratings on both Gilead and Infinity.
News For GILD;INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
14:15 EDTGILDGilead October weekly 113 straddle priced for 5% move into Q3
Subscribe for More Information
13:20 EDTGILDGilead volatility increases into Q3 and outlook
Gilead October weekly call option implied volatility is at 69, November is at 43, December is at 40, and January is at 37; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
09:37 EDTGILDActive equity options trading
Subscribe for More Information
October 27, 2014
16:00 EDTGILDOptions Update; October 27, 2014
iPath S&P 500 VIX Short-Term Futures down 52c to 32.66. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR TWTR AMZN M NQ GILD C FB NFLX
08:27 EDTGILDGilead volatility elevated into Q3 and outlook
Gilead October weekly call option implied volatility is at 63, November is at 38, December and January is at 33; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
07:22 EDTGILDAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
16:02 EDTGILDOptions Update; October 24, 2014
Subscribe for More Information
11:55 EDTGILDStocks with call strike movement; YHOO GILD
Subscribe for More Information
October 23, 2014
08:35 EDTGILDGilead weekly volatility increases into Q3 and outlook
Gilead October weekly 31 call option implied volatility is at 43, December and January is at 33; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
October 22, 2014
09:38 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR YHOO BAC GILD FB THRX DOW CAR
07:35 EDTGILDCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR CVX VZ MCD GILD TXN
08:45 EDTGILDGilead Hep C drug barely used in California prisons due to cost, SFGate reports
Subscribe for More Information
October 20, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:04 EDTINFIInfinity Pharmaceuticals coverage resumed with a Hold at Stifel
October 17, 2014
16:01 EDTGILDOptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
09:38 EDTGILDActive equity options trading on
Subscribe for More Information
October 16, 2014
13:31 EDTGILDGilead announces Harvoni Notice of Compliance from Health Canada
Gilead Sciences announced that Health Canada has issued a Notice of Compliance for Harvoni. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, granted marketing authorization under the tradename Sovaldi in December 2013. The efficacy of Harvoni has been established in patients with chronic hepatitis C virus genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naive patients without cirrhosis who have baseline HCV viral load below 6M IU/mL. New Drug Submission applications are pending in Australia and New Zealand.
07:41 EDTINFIInfinity reports duvelisib Phase 2a primary endpoint not met
Infinity Pharmaceuticals announced encouraging topline data from its Phase 2a exploratory study of duvelisib, or IPI-145. Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement was observed in the late-phase asthmatic response FEV1 among patients who received duvelisib administered at the highest dose tested, 25 mg twice daily for five days, however the primary endpoint of the study was not met as it did not reach statistical significance. Multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance and were associated with changes in key cytokines and chemokines involved in the asthmatic response. Taken together, these data demonstrate early proof-of-activity in this allergen challenge study. Infinity expects to present the final data in a peer-reviewed setting after all analyses are complete. In addition, the company anticipates determining its next steps for development of PI3K-delta,gamma inhibitors in inflammation after evaluating the results from the ASPIRA study in rheumatoid arthritis, which are expected by the end of 2014.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use